Glenmark Pharmaceuticals Limited Max Pain Analysis
What is Max Pain?
Max Pain theory states the underlying gravitates toward the strike where option writers face minimum collective loss at expiry. For GLENMARK, that strike is ₹2,260. Spot at ₹2,300 is 1.77% above max pain — possible downward gravitational pull into expiry.
Max Pain Level
The options market shows a concentration of open interest at the ₹2,260 strike, which is identified as the max‑pain level for GLENMARK. This is the price at which option writers would experience the smallest aggregate loss, creating a magnetic pull toward that strike as expiry approaches.
Spot vs Max Pain Gap
The current spot price of ₹2,300 sits about 1.77 % above the max‑pain level, indicating a modest upward gap. If the underlying drifts lower, the gap could close, reinforcing the pull toward ₹2,260; a sustained gap may require a stronger catalyst to keep the price above that threshold.
Shift Signal
The max‑pain figure has moved up 20 points from yesterday, suggesting that option writers have added new positions at slightly higher strikes. This upward shift reflects a bias toward protecting against further upside, while still leaving enough open interest below to maintain the pain magnet.
Expiry Context
As the 2026‑11‑23 expiry date draws nearer, the concentration of open interest at the max‑pain strike typically intensifies the incentive for market participants to shepherd the price toward that level. However, max pain is a statistical tendency, not a deterministic outcome; external news, earnings, or macro events can easily override the pull.
Data Note
With 26 days remaining, the spot is ₹40 above the max‑pain level of ₹2,260.
Data as of 2026-10-28